Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.180
-0.080 (-6.35%)
At close: Jun 27, 2025, 4:00 PM
1.240
+0.060 (5.08%)
After-hours: Jun 27, 2025, 7:57 PM EDT
Company Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.
It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Zentalis Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 166 |
| CEO | Julie Eastland |
Contact Details
Address: 10275 Science Center Dr., Suite 200 San Diego, California 92121 United States | |
| Phone | 212 433 3791 |
| Website | zentalis.com |
Stock Details
| Ticker Symbol | ZNTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001725160 |
| CUSIP Number | 98943L107 |
| ISIN Number | US98943L1070 |
| Employer ID | 82-3607803 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Julie M. Eastland M.B.A. | Chief Executive Officer, President and Director |
| Andrea Paul J.D. | Chief Legal Officer and Corporate Secretary |
| Vincent A. Vultaggio | SVice President of Finance and Principal Accounting Officer |
| Wendy Chang | Chief People Officer |
| Kimberly Freeman | Chief Strategy Officer |
| Dr. Ingmar Bruns M.D., Ph.D. | Chief Medical Officer |
| Haibo Wang | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2025 | 8-K | Current Report |
| Jun 2, 2025 | 8-K | Current Report |
| May 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 20, 2025 | 8-K | Current Report |
| May 14, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | SCHEDULE 13G/A | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |